Effects of anti-CD20 therapy on circulating and intrathecal follicular helper T cell subsets in multiple sclerosis

被引：0

作者：

El Mahdaoui, Sahla ^{[1
,3
]}

Hansen, Marie Mathilde ^{[1
]}

Hansen, Malene Bredahl ^{[1
]}

Hvalkof, Victoria Hyslop ^{[1
]}

Ondergaard, Helle Bach S. ^{[1
]}

Mahler, Mie Reith ^{[1
]}

Christensen, Jeppe Romme ^{[1
]}

Sellebjerg, Finn ^{[1
,2
]}

von Essen, Marina Rode ^{[1
]}

机构：

[1] Copenhagen Univ Hosp, Danish Multiple Sclerosis Ctr, Dept Neurol, Rigshosp, Glostrup, Denmark

[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark

[3] Danish Multiple Sclerosis Ctr, Rigshosp, Valdemar Hansens Vej 13, DK-2600 Glostrup, Denmark

来源：

CLINICAL IMMUNOLOGY | 2024年 / 264卷

关键词：

CD4; Ocrelizumab; Rituximab; CXCR5; B-cell depletion; CXCL13; CEREBROSPINAL-FLUID; B-CELLS; RITUXIMAB; DIAGNOSIS; PLACEBO; CXCL13;

D O I：

10.1016/j.clim.2024.110262

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Follicular helper T (Tfh) cells and their interplay with B cells likely contribute to the pathogenesis of relapsingremitting multiple sclerosis (RRMS). Tfh cells are enriched in cerebrospinal fluid (CSF) in RRMS, but effects of anti-CD20 therapy are unknown. We investigated Tfh cells in controls, untreated and anti-CD20-treated patients with RRMS using flow cytometry. CSF Tfh cells were increased in untreated patients. Compared to paired blood samples, CD25 - Tfh cells were enriched in CSF in RRMS, but not in controls. Contrast-enhancing brain MRI lesions and IgG index correlated with CSF CD25 - Tfh cell frequency in untreated patients with RRMS. Anti-CD20 therapy reduced the numbers of circulating PD1 + Tfh cells and CD25 - Tfh cells, and the frequency of CSF CD25 - Tfh cells. The study suggests that CD25 - Tfh cells are recruited to the CSF in RRMS, associated with focal inflammation, and are reduced by anti-CD20 therapy.

引用

页数：8

共 50 条

[1] Development of anti-CD20 therapy for multiple sclerosis
Bartok, Beatrix
Silverman, Gregg J. J.
[J]. EXPERIMENTAL CELL RESEARCH, 2011, 317 (09) : 1312 - 1318
[2] Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis
Howlett-Prieto, Quentin
Feng, Xuan
Kramer, John F.
Kramer, Kevin J.
Houston, Timothy W.
Reder, Anthony T.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (14) : 2170 - 2179
[3] Effects of anti-CD20 monoclonal antibody therapy on cerebrospinal fluid B cell subsets in relapsing-remitting multiple sclerosis
El Mahdaoui, S.
Hansen, M. M.
von Essen, M.
Sellebjerg, F.
Christensen, J. Romme
[J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 840 - 840
[4] Unraveling the T-B tangle in anti-CD20 multiple sclerosis therapy
Waisman, Ari
Ebering, Anna
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (51) : 25376 - 25377
[5] Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy
Heming, Michael
Wiendl, Heinz
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (06)
[6] Repeated iv anti-CD20 treatment in multiple sclerosis: Long-term effects on peripheral immune cell subsets
Feige, Julia
Moser, Tobias
Akguen, Katja
Schwenker, Kerstin
Hitzl, Wolfgang
Haschke-Becher, Elisabeth
Ziemssen, Tjalf
Sellner, Johann
[J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (02): : 450 - 465
[7] Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
Roach, Charles A.
Cross, Anne H.
[J]. FRONTIERS IN NEUROLOGY, 2021, 11
[8] Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
Gross, Catharina C.
Schulte-Mecklenbeck, Andreas
Klinsing, Svenja
Posevitz-Fejfar, Anita
Wiendl, Heinz
Klotz, Luisa
[J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2016, 3 (01):
[9] Anti-CD20 monoclonal antibodies in multiple sclerosis
Moreno Torres, Irene
Garcia-Merino, Antonio
[J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2017, 17 (04) : 359 - 371
[10] Anti-CD20 antibody wows in multiple sclerosis
Sheridan, Cormac
[J]. NATURE BIOTECHNOLOGY, 2015, 33 (12) : 1215 - 1216

← 1 2 3 4 5 →